Adil Jadoon1, Anna V Mathew1, Jaeman Byun1, Crystal A Gadegbeku2, Debbie S Gipson3, Farsad Afshinnia1, Subramaniam Pennathur1,4. 1. Department of Internal Medicine-Nephrology, University of Michigan, Ann Arbor, Michigan, USA. 2. Department of Internal Medicine-Nephrology, Temple University, Philadelphia, Pennsylvania, USA. 3. Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA. 4. Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
BACKGROUND: The gut microbiota is altered in patients with chronic kidney disease (CKD), and cardiovascular risk increases with progressive CKD. This study examined the potential link between short chain fatty acids (SCFAs), which are produced by the gut microbiota, and cardiovascular outcomes in patients with CKD. METHODS:SCFAs were measured using a targeted liquid chromatography-mass spectrometry platform in baseline plasma samples from 214 patients with CKD enrolled in the Clinical Phenotyping Resource and Biobank Core; 81 patients with coronary artery disease (CAD) and 133 without CAD were randomly assigned to training and validation subsets. The primary outcome was a history of CAD and the secondary outcome was a composite history of cardiovascular disease (CVD) at enrollment. RESULTS: We found significantly higher levels of the SCFA valerate among patients with CAD as compared with patients without CAD in the training set (p < 0.001). The valerate concentrations were also significantly higher among subjects with composite outcomes of CVD compared to those without CVD (p = 0.006). These results were subsequently replicated in the validation set. Logistic regression analysis revealed a strong independent association between plasma valerate levels and CVD in both training and validation sets. When valerate was added to the base clinical model comprising of diabetes, hypertension, urinary protein-creatinine ratio, and estimated glomerular filtration rate, it increased the c-statistics for predicting CVD from 0.68 to 0.79 (p = 0.02) in the training set, an observation which was confirmed in the validation set. - Conclusion: This study provides evidence for alterations in gut-microbiota-derived SCFAs with advancing CKD, demonstrates the association of higher plasma valerate levels with pre-existing CVD, and reveals areas for future exploration of cardiovascular risk in patients with CKD.
RCT Entities:
BACKGROUND: The gut microbiota is altered in patients with chronic kidney disease (CKD), and cardiovascular risk increases with progressive CKD. This study examined the potential link between short chain fatty acids (SCFAs), which are produced by the gut microbiota, and cardiovascular outcomes in patients with CKD. METHODS: SCFAs were measured using a targeted liquid chromatography-mass spectrometry platform in baseline plasma samples from 214 patients with CKD enrolled in the Clinical Phenotyping Resource and Biobank Core; 81 patients with coronary artery disease (CAD) and 133 without CAD were randomly assigned to training and validation subsets. The primary outcome was a history of CAD and the secondary outcome was a composite history of cardiovascular disease (CVD) at enrollment. RESULTS: We found significantly higher levels of the SCFA valerate among patients with CAD as compared with patients without CAD in the training set (p < 0.001). The valerate concentrations were also significantly higher among subjects with composite outcomes of CVD compared to those without CVD (p = 0.006). These results were subsequently replicated in the validation set. Logistic regression analysis revealed a strong independent association between plasma valerate levels and CVD in both training and validation sets. When valerate was added to the base clinical model comprising of diabetes, hypertension, urinary protein-creatinine ratio, and estimated glomerular filtration rate, it increased the c-statistics for predicting CVD from 0.68 to 0.79 (p = 0.02) in the training set, an observation which was confirmed in the validation set. - Conclusion: This study provides evidence for alterations in gut-microbiota-derived SCFAs with advancing CKD, demonstrates the association of higher plasma valerate levels with pre-existing CVD, and reveals areas for future exploration of cardiovascular risk in patients with CKD.
Authors: Aurélien Trompette; Eva S Gollwitzer; Koshika Yadava; Anke K Sichelstiel; Norbert Sprenger; Catherine Ngom-Bru; Carine Blanchard; Tobias Junt; Laurent P Nicod; Nicola L Harris; Benjamin J Marsland Journal: Nat Med Date: 2014-01-05 Impact factor: 53.440
Authors: Nosratola D Vaziri; Jakk Wong; Madeleine Pahl; Yvette M Piceno; Jun Yuan; Todd Z DeSantis; Zhenmin Ni; Tien-Hung Nguyen; Gary L Andersen Journal: Kidney Int Date: 2012-09-19 Impact factor: 10.612
Authors: Julia K Goodrich; Jillian L Waters; Angela C Poole; Jessica L Sutter; Omry Koren; Ran Blekhman; Michelle Beaumont; William Van Treuren; Rob Knight; Jordana T Bell; Timothy D Spector; Andrew G Clark; Ruth E Ley Journal: Cell Date: 2014-11-06 Impact factor: 41.582
Authors: W H Wilson Tang; Zeneng Wang; Bruce S Levison; Robert A Koeth; Earl B Britt; Xiaoming Fu; Yuping Wu; Stanley L Hazen Journal: N Engl J Med Date: 2013-04-25 Impact factor: 91.245
Authors: Fellype C Barreto; Daniela V Barreto; Sophie Liabeuf; Natalie Meert; Griet Glorieux; Mohammed Temmar; Gabriel Choukroun; Raymond Vanholder; Ziad A Massy Journal: Clin J Am Soc Nephrol Date: 2009-08-20 Impact factor: 8.237
Authors: Xiaohong Tracey Gan; Grace Ettinger; Cathy X Huang; Jeremy P Burton; James V Haist; Venkatesh Rajapurohitam; James E Sidaway; Glynn Martin; Gregory B Gloor; Jonathan R Swann; Gregor Reid; Morris Karmazyn Journal: Circ Heart Fail Date: 2014-03-13 Impact factor: 8.790
Authors: Chelsea L Organ; Hiroyuki Otsuka; Shashi Bhushan; Zeneng Wang; Jessica Bradley; Rishi Trivedi; David J Polhemus; W H Wilson Tang; Yuping Wu; Stanley L Hazen; David J Lefer Journal: Circ Heart Fail Date: 2015-12-23 Impact factor: 8.790
Authors: Marco A R Vinolo; G John Ferguson; Suhasini Kulkarni; George Damoulakis; Karen Anderson; Mohammad Bohlooly-Y; Len Stephens; Phillip T Hawkins; Rui Curi Journal: PLoS One Date: 2011-06-15 Impact factor: 3.240
Authors: Peter McGranaghan; Jennifer A Kirwan; Mariel A Garcia-Rivera; Burkert Pieske; Frank Edelmann; Florian Blaschke; Sandeep Appunni; Anshul Saxena; Muni Rubens; Emir Veledar; Tobias Daniel Trippel Journal: Metabolites Date: 2021-09-14
Authors: Bernadette Jones-Freeman; Michelle Chonwerawong; Vanessa R Marcelino; Aniruddh V Deshpande; Samuel C Forster; Malcolm R Starkey Journal: Mucosal Immunol Date: 2021-02-04 Impact factor: 7.313